<code id='BAB734E400'></code><style id='BAB734E400'></style>
    • <acronym id='BAB734E400'></acronym>
      <center id='BAB734E400'><center id='BAB734E400'><tfoot id='BAB734E400'></tfoot></center><abbr id='BAB734E400'><dir id='BAB734E400'><tfoot id='BAB734E400'></tfoot><noframes id='BAB734E400'>

    • <optgroup id='BAB734E400'><strike id='BAB734E400'><sup id='BAB734E400'></sup></strike><code id='BAB734E400'></code></optgroup>
        1. <b id='BAB734E400'><label id='BAB734E400'><select id='BAB734E400'><dt id='BAB734E400'><span id='BAB734E400'></span></dt></select></label></b><u id='BAB734E400'></u>
          <i id='BAB734E400'><strike id='BAB734E400'><tt id='BAB734E400'><pre id='BAB734E400'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:entertainment    Page View:99
          Fetal ultrasound
          Adobe

          The artificial womb, a device aiming to save infants born way too soon, is inching closer to being tested in humans.

          The technology is close enough to reality that the Food and Drug Administration has decided to convene a two-day panel starting Tuesday to discuss how to best evaluate safety and effectiveness, as well as the ethical quandaries in running clinical trials. The second day will be closed to the public to shield trade secrets.

          advertisement

          Several research teams are racing to build artificial placentas that replicate the uterine environment and give the very prematurely born a better shot at survival. A team at the Children’s Hospital of Philadelphia, led by Alan Flake, is the closest to human trials — their device is a bag filled with sterile fluid, which contains the fetus and is connected to tubes providing oxygen and nutrition.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Readout Newsletter: Bayer study halts, Carmot to IPO, and more
          Readout Newsletter: Bayer study halts, Carmot to IPO, and more

          KenaBetancur/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbi

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          At Orexo, a ‘turning point’ for everything but digital health

          AdobeMosteverythingislookingupforOrexo,thecompanyreportedonitssecondquarterearningscallonTuesday.Tha